Context
Generalized anxiety disorder (GAD) is a chronic and disabling disorder characterized by excessive anxiety and uncontrollable worry about everyday life. For a definitive diagnosis, patients will also have at least three of the following symptoms: restlessness, difficulty concentrating, sleep disturbances, irritability, muscle tension, and becoming easily fatigued. More common in women, the lifetime prevalence of GAD is estimated to be as high as 6.6%. GAD is often seen together with other conditions such as panic disorder, phobias, obsessive compulsive disorder, depression, and health anxiety. Medication is the primary treatment modality for GAD and may be accompanied by psychological treatment such as cognitive behavioural therapy.

Technology
Selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine and noradrenaline reuptake inhibitors (SNRIs) are first-line drugs for the treatment of GAD. While effective, they can produce adverse events and have a slower onset of action during which anxiety may increase. Benzodiazepines (BZDs) are a class of drugs commonly used to treat anxiety disorders that work to decrease nerve activity in the brain. Although they work quickly to treat anxiety in the short-term, they may result in adverse events, dependency, and substance abuse over the long-term.

Issue
A review of systematic reviews and evidence-based clinical practice guidelines on the short- and long-term use of BZDs in patients with GAD will help to inform decisions about GAD therapy.

Methods
A limited literature search was conducted of key resources, and titles and abstracts of the retrieved publications were reviewed. Full-text publications were evaluated for final article selection according to predetermined selection criteria (population, intervention, comparator, outcomes, and study designs).

Key Messages
Short-term BZDs for GAD is recommended:
• for patients taking antidepressants but not yet responding
• for patients in acute crisis
• for patients whose anxiety has increased.

Long-term BZD use in GAD is not recommended unless:
• patients cannot tolerate or do not respond to first-line pharmacotherapies.

The maximum daily dose for long-term BZD therapy in GAD is uncertain.

Caution is advised for the elderly, children, and for pregnant or breastfeeding woman.

Results
The literature search identified 316 citations, 10 of which were deemed potentially relevant. An additional 6 articles were identified from other sources. Of these 16 reports, 6 met the criteria for inclusion in this review: 2 systematic reviews and 4 evidence-based guidelines.

DISCLAIMER: The information in this Report in Brief is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this Report in Brief should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the Report in Brief to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this Report in Brief.

CADTH takes sole responsibility for the final form and content of this Report in Brief. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government. Production of this Report in Brief is made possible through a financial contribution from Health Canada.

RC0567